Alpha DNA Investment Management’s ResMed RMD Stock Holding History

Alpha DNA Investment Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,355	Closed	-$767K	–	147
2024 Q4	$767K	Buy	+3,355	New	+$808K	0.29%	78

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Alpha DNA Investment Management's RMD Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of ResMed (RMD) in Q1 2025, closing a stake of 3,355 shares — an estimated $767K sold.

Alpha DNA Investment Management first reported a position in RMD in Q4 2024 and held it in 1 quarter. The position peaked at $767K in Q4 2024. 885 funds tracked by Wall St. Rank hold RMD as of Q1 2025.

Alpha DNA Investment Management reported no remaining ResMed position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 3,355 ResMed shares in Q1 2025, an estimated $767K.
Alpha DNA Investment Management first reported a position in ResMed in Q4 2024 and held it in 1 quarter.
Alpha DNA Investment Management's ResMed position peaked at $767K in Q4 2024.
885 funds tracked by Wall St. Rank held ResMed as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.